PD-1T TILs as precision biomarker in NSCLC 75 2 Table S3. Continued Training cohort Validation cohort n=43 n=77 DC 6 months P=0.68 33% (14/43) 29% (22/77) 12 months P=0.25 28% (12/43) 18% (14/77) s.d., standard deviation; IQR, interquartile range; PS, Performance Score, based on the European Cooperative Oncology group (ECOG) performance status score. This is a score ranging from 0 to 5, where 0 indicates no symptoms, 1 indicates mild symptoms and above 1 indicates greater disability; LCNEC NSCLC type, large cell neuroendocrine carcinoma nonsmall cell lung cancer type; NOS, not otherwise specified; KRAS, Kirsten Rat Sarcoma viral oncogene; PD-L1, programmed death ligand 1; TPS, tumor proportion score; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; DC, disease control. Table S4. Tissue sample properties of the training and validation set. Training cohort Validation cohort n=43 n=77 Sample type P=0.33 Biopsy 30 (70%) 58 (75%) Resection 13 (30%) 19 (25%) Sample site P=0.46 Primary 19 (44%) 32 (41%) Metastasis 16 (37%) 36 (47%) Lung 1 5 Adrenal gland 3 7 Bone 0 7 Pleurae 0 1 Brain 0 2 Muscle / Subcutaneous 3 8 Liver 6 3 Mamma 2 1 Gastrointestinal 1 2 Lymph node metastasis 8 (19%) 9 (12%)
RkJQdWJsaXNoZXIy MTk4NDMw